Disease on EC 2.6.1.16 - glutamine-fructose-6-phosphate transaminase (isomerizing)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Breast Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Carcinoma, Hepatocellular
Characterization of rat hepatoma glucosamine 6-phosphate synthase and its relation to liver and fetal forms.
Comparison of the properties of glucosaminephosphate isomerase (glutamine-forming) from rat liver and a hepatoma.
choline o-acetyltransferase deficiency
Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.
Diabetes Complications
Expression and purification of active human internal His(6)-tagged L-glutamine: D-Fructose-6P amidotransferase I.
Diabetes Mellitus, Type 2
Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels.
Effect of +36T>C in intron 1 on the glutamine: fructose-6-phosphate amidotransferase 1 gene and its contribution to type 2 diabetes in different populations.
Expression and purification of active human internal His(6)-tagged L-glutamine: D-Fructose-6P amidotransferase I.
From Lobry de Bruyn to enzyme-catalyzed ammonia channelling: molecular studies of D-glucosamine-6P synthase.
Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress.
Glutamine: fructose-6-phosphate amidotransferase (GFAT): homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol.
Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin.
Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM.
Structural analysis of human glutamine:fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes.
Diabetic Angiopathies
Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells.
Diabetic Nephropathies
Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels.
Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells.
Molecular screening of the human glutamine-fructose-6-phosphate amidotransferase 1 (GFPT1) gene and association studies with diabetes and diabetic nephropathy.
Overexpression of GFAT activates PAI-1 promoter in mesangial cells.
Scrutiny of the glutamine-fructose-6-phosphate transaminase 1 (GFPT1) locus reveals conserved haplotype block structure not associated with diabetic nephropathy.
Glucose Intolerance
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
glutamine-fructose-6-phosphate transaminase (isomerizing) deficiency
Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.
Glycogen Storage Disease Type II
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Hyperglycemia
A Genetic Model to Study Increased Hexosamine Biosynthetic Flux.
Glucose catabolic gene mRNA levels in skeletal muscle exhibit non-coordinate expression in hyperglycemic mice.
Overexpression of GFAT activates PAI-1 promoter in mesangial cells.
The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects.
Hyperlipidemias
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
Infection
Molecular docking based screening of G6PS with 1, 5 Benzothiazepine derivates for a potential inhibitor.
Insulin Resistance
A Genetic Model to Study Increased Hexosamine Biosynthetic Flux.
Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance.
Cloning and characterization of mouse glutamine:fructose-6-phosphate amidotransferase 2 gene promoter.
Differential effects of GLUT1 or GLUT4 overexpression on hexosamine biosynthesis by muscles of transgenic mice.
Glucosamine-6-phosphate synthase--the multi-facets enzyme.
Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress.
Hexosamine biosynthesis pathway flux contributes to insulin resistance via altering membrane phosphatidylinositol 4,5-bisphosphate and cortical filamentous actin.
Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle.
Increased hexosamine pathway flux and high fat feeding are not additive in inducing insulin resistance: evidence for a shared pathway.
Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione.
Molecular characterization, chromosomal location, alternative splicing and polymorphism of porcine GFAT1 gene.
Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase.
Molecular therapeutic target for type-2 diabetes.
New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids.
Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance.
Regulation of insulin-stimulated glycogen synthase activity by overexpression of glutamine: fructose-6-phosphate amidotransferase in rat-1 fibroblasts.
Select nutrients, progesterone, and interferon tau affect conceptus metabolism and development.
Leukemia L1210
The influence of L-norvalyl-N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic acid, an antifungal agent, on mammalian cells in tissue culture.
Lung Neoplasms
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Malaria
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
Metabolic Syndrome
Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet.
Muscle Weakness
Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.
Muscular Diseases
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.
Muscular Dystrophies
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Muscular Dystrophies, Limb-Girdle
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Myasthenic Syndromes, Congenital
A 3'-UTR mutation creates a microRNA target site in the GFPT1 gene of patients with congenital myasthenic syndrome.
Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Limb-girdle myasthenia with tubular aggregates associated with novel GFPT1 mutations.
Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.
Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.
Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy.
Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.
Mycoses
Functional co-evolutionary study of glucosamine-6-phosphate synthase in mycoses causing fungi.
Purification to homogeneity of Candida albicans glucosamine-6-phosphate synthase overexpressed in Escherichia coli.
Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Carcinofetal alterations in glucosamine-6-phosphate synthetase.
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Hyaluronan Production Regulates Metabolic and Cancer Stem-like Properties of Breast Cancer Cells via Hexosamine Biosynthetic Pathway-coupled HIF-1 Signaling.
Neuromuscular Junction Diseases
Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.
Obesity
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
The -913 G/A glutamine:fructose-6-phosphate aminotransferase gene polymorphism is associated with measures of obesity and intramyocellular lipid content in nondiabetic subjects.
Pancreatic Neoplasms
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.
Pulmonary Fibrosis
Elevation of glucosamine 6-phosphate synthetase activity in bleomycin-induced pulmonary fibrosis in hamsters.
Peplomycin sulfate and pulmonary fibrosis: hydroxyproline, uronic acid, proline hydroxylase and glucosamine 6-phosphate synthetase in lungs of hamsters treated with peplomycin.
Small Cell Lung Carcinoma
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Stomach Ulcer
Aminosugars in cases of gastric ulcers. II. The activity of L-glutamine: D-fructose-6-phosphate aminotransferase (E. C. 2.6.1.16) in human gastric mucous membrane.
Triple Negative Breast Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.